 Press Release Distribution |
 |
- PR Home
- Latest News
- Feeds
- Alerts
- Submit Free Press Release
- Journalist Account
- PRNewswire Distribution
Filter News Show All ResultsNews By Country
News By Tag Rna  Related Tags Aids
Aids Scandal Antibodies Cancer DNA Egyptian Fintan Steele Gay Hepatitis Hiv Hot Jihad Lna Love Microarrays Nucleic Acid Therapeutics Oligonucleotides Rna Corp Silicon Stunny Pharouk
| rna Latest News+ XML/RSSBy Mary Ann Liebert, Inc., publishers New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge. By Mary Ann Liebert, Inc., publishers By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease. By Mary Ann Liebert, Inc., publishers As scientists continue to unravel the complexity of the human genome and to uncover vital elements that play a role in both normal physiology and disease, one particular class of elements called noncoding RNAs is gaining a lot of attention. By Particular GmbH While the gold price keeps setting new records, nanoparticles from pure gold are also gaining importance in biotechnology. Particular GmbH from Germany now uses a laser method to produce them with high purity and conjugate them with high efficiency. All Press ReleasesBy Mary Ann Liebert, Inc., publishers New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge. By Mary Ann Liebert, Inc., publishers By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease. By Mary Ann Liebert, Inc., publishers As scientists continue to unravel the complexity of the human genome and to uncover vital elements that play a role in both normal physiology and disease, one particular class of elements called noncoding RNAs is gaining a lot of attention. By Mary Ann Liebert, Inc., publishers Small interfering RNAs (siRNAs) are a potent new drug class that can silence a disease-causing gene, but delivering them to a target cell can be challenging. By Mary Ann Liebert, Inc., publishers The use of RNA in nanotechnology applications is highly promising for many applications, including the development of new therapeutic compounds. By AnaSpec EGT Group The detection of nucleic acids is important for many life science research tasks, such as sequencing, cDNA synthesis and cloning, RNA transcription and transfection. By biosyn.com Bio-Synthesis is able to synthesize ultra long oligonucleotides (RNA and DNA). By Mary Ann Liebert, Inc., publishers Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity. By Shridhar University Even though the proponents of a natural origin of life expressed much optimism for providing their theories, presently there is a detailed compilation of information seriously questioning this doctrine. By Particular GmbH While the gold price keeps setting new records, nanoparticles from pure gold are also gaining importance in biotechnology. Particular GmbH from Germany now uses a laser method to produce them with high purity and conjugate them with high efficiency. By Freedom Press New Book “Extraordinary Healing” recounts life and research of French molecular biologist Dr. Mirko Beljanski By Insight Pharma Reports RNAi Therapeutics: Second-Generation Candidates Build Momentum By Bharatbook Bharatbook added a new report on "Global miRNA Market Outlook" which provides a comprehensive overview of the miRNA market and its prospects. By RNCOS. By Melanie Bernds Dr. William H. Danforth, chairman of the Board of Trustees of the Donald Danforth Plant Science Center, today announced that Dr. James C. Carrington, will become the next President of the Danforth Plant Science Center. By Insight Pharma Reports Cambridge Healthtech Institute (CHI) releases its latest Insight Pharma Report, Next-Generation Sequencing Technologies: Applications and Markets, available at InsightPharmaReports.com By Bill Schappert Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity. A review article published online ahead of print in Oligonucleotides. By Gerry Skews SERVA Electrophoresis introduce the Blue Power range of Programmable Laboratory Power Supplies. By Gerry Skews SERVA DNA Stain G is a safer alternative to traditional ethidium bromide stain for detecting nucleic acid in agarose gels. By LevelStock.com Investors seeking technical and fundamental stock alerts on penny stocks can subscribe to our newsletters today at LevelStock.com By Tacere Therapeutics, Inc. Pfizer exercises option to further develop and commercialize Tacere’s Hepatitis C Virus (HCV) compounds. By Bharatbook Bharatbook added a new report on "Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma" which gives in-depth analysis on RNA Therapeutics Market. By Bio-Synthesis, Inc. Bio-Synthesis, Inc. provides custom products for researchers and pharmaceutical companies By Angela Ragan The new uses and benefits of anti-drug antibodies, examined by Bio-Synthesis, Inc. By Bio-Synthesis, Inc. Bio-Synthesis has teamed up with BioConference Live for a revolutionary event. BioConference Live is a free, online-only conference for the life sciences and laboratory science community. By Fred Schlegel GenUs BioSystems announces a combined miRNA and whole genome gene expression service. Standard combined service for yields as low as 400 nanograms. Special application services are also available for much smaller yields. By Fred Schlegel GenUs BioSystems announces a 70% reduction in the minimum RNA yield requirement for standard gene expression services to 300 nanograms. Special services are available for yields down to 100 picograms RNA. By Mary Ann Liebert, Inc., publishers A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases By Mary Ann Liebert, Inc., publishers Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects By Trana Discovery, Inc. Drug discovery technology company develops tools to find new treatments for serious infectious diseases… By Colfax International RNA Networks’ Memory Virtualization Platform Improves HPC Performance and Analysis By Mary Ann Liebert, Inc., publishers Systems biology scientists from diverse areas of research are developing a range of methods to model pathways, interpret data, and derive therapeutic targets from biological networks, reports Genetic Engineering and Biotechnology News (GEN). By Bharatbook Bharatbook.com is glad to promote new report which focuses on RNA interference markets By Mary Ann Liebert, Inc., publishers RNAi represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing applications of RNAi and microRNAs will begin in Human Gene Therapy. Page:
| ||||||||||||||||||||||
Like PRLog?
8.4K1.9K2.6K